Updates are available Correction dated 2022-12-27
Click to view Correction: https://doi.org/10.1186/s13223-022-00754-3
-
Authors
Meltzer, Eli O.
Rosario, Nelson Augusto
Van Bever, Hugo
Lucio, Luiz https://orcid.org/0000-0002-3895-7612
-
Funding
Funding for this research was provided by:
sanofi
- License Information
-
More Information
Article History
Received: 13 July 2021
Accepted: 8 October 2021
First Online: 2 November 2021
Change Date: 27 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13223-022-00754-3
Declarations
:
: Not applicable
: Not applicable.
: EOM is a speaker for, a member of an advisory board for ALK, GlaxoSmithKline, Glenmark, Merck, Mylan and Regeneron/SanofiGenzyme, a consultant or advisory board member for AstraZeneca, Axdev, Boehringer Ingelheim, Church & Dwight, GossamerBio, Novartis and Principia. NAR is a speaker for Takeda, a speaker and a member of an advisory board for Sanofi, Boehringer Ingelheim, AstraZeneca, Chiesi and Mylan and reports research grants from Sanofi, Vertex, AstraZeneca and Janssen. HVB has no conflicts of interest to disclose. LL was an employee of Sanofi and may hold shares and/or stock options in the company.
